Aclaris Therapeutics Inc

Slēgts

5.57 4.31

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

5.42

Max

5.57

Galvenie mērījumi

By Trading Economics

Ienākumi

-29K

-20M

Pārdošana

701K

2M

EPS

-0.15

Peļņas marža

-993.186

Darbinieki

69

EBITDA

-29K

-20M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+91.91% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 5. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

57M

689M

Iepriekšējā atvēršanas cena

1.26

Iepriekšējā slēgšanas cena

5.57

Aclaris Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. jūl. 23:51 UTC

Macro News
Correlated Moves

Bitcoin is higher as the Trump administration advances plans for a Strategic Bitcoin Reserve, with a federal purchase expected by Q4 2026.

2026. g. 4. jūl. 23:41 UTC

Canada's Balance of Trade data set for July 7, 2026, forecasts a C$2.4 billion surplus amid cautious market optimism despite geopolitical tensions and U.S.-Canada trade concerns.

2026. g. 4. jūl. 23:41 UTC

Brazil's July Inflation Rate Release Sparks Caution Amid Mixed Economic Signals and Global Monetary Policy Shifts

2026. g. 4. jūl. 23:41 UTC

Brazil's June 2026 Inflation Rate Release Sparks Cautious Optimism Amid Easing Pressures and Global Economic Influences

2026. g. 4. jūl. 23:41 UTC

Mexico's June 2026 Inflation Rate Release on July 9 Expected to Influence Market Sentiment Amid Global Economic Trends.

2026. g. 4. jūl. 23:41 UTC

U.S. Exports Data Release on July 7, 2026, Expected to Reflect Resilience Amid Geopolitical Tensions and Market Optimism Following Record Highs

2026. g. 4. jūl. 23:41 UTC

Mexico's Inflation Rate MoM Release on July 9 Expected to Reflect Global Economic Pressures Amid U.S. Monetary Policy Concerns.

2026. g. 4. jūl. 23:41 UTC

U.S. Imports Data Release on July 7, 2026: Market Anticipates Impact of Tariffs and Global Trade Dynamics Amid Cautious Optimism for Economic Stabilization.

2026. g. 4. jūl. 23:41 UTC

U.S. Trade Deficit Expected at $78.8 Billion Amid Weak Job Growth and Easing Geopolitical Tensions

2026. g. 4. jūl. 23:32 UTC

Cryptocurrency Market Gains Amid Weak U.S. Job Data and Cautious Fed Outlook

2026. g. 4. jūl. 23:32 UTC

Bitcoin and Ethereum rise amid positive market sentiment following disappointing U.S. jobs data and easing geopolitical tensions, while investors anticipate key economic releases next week.

2026. g. 4. jūl. 23:32 UTC

U.S. job growth disappoints, shifting Fed rate hike expectations, while Eurozone PMI stabilizes and car registrations surge in Germany.

2026. g. 4. jūl. 23:32 UTC

Cryptocurrency market shows recovery as Bitcoin and Ethereum post gains, while U.S. job growth disappoints, reducing Fed rate hike expectations ahead of July FOMC meeting.

2026. g. 4. jūl. 23:21 UTC

Macro News
Correlated Moves

Ethereum is advancing today, buoyed by Federal Reserve Chair Kevin Warsh's remarks on easing inflation risks and strong market interest ahead of Pepeto's presale.

2026. g. 4. jūl. 23:11 UTC

Correlated Moves

The Russell 2000 Index is trading lower in after-market hours, reflecting a decline since Friday's close amid limited momentum and macroeconomic influences.

2026. g. 4. jūl. 23:11 UTC

Correlated Moves

After-market trading for the Dow Jones Index shows a decline, reflecting a cumulative drop since Friday's close amid shared macroeconomic factors with the S&P 500.

2026. g. 4. jūl. 23:01 UTC

The FTSE 100 Index is lower in after-hours trading, reversing earlier gains. It remains above its 20-day moving average and near its one-month range.

2026. g. 4. jūl. 23:01 UTC

Correlated Moves

Cardano is rising, supported by Ethereum's gains and positive market sentiment. The asset remains above its 20-day moving average, with strong performance over four sessions.

2026. g. 4. jūl. 23:01 UTC

Macro News

The S&P 500 Index is lower in after-market hours amid rising memory chip costs and escalating geopolitical tensions following a Ukrainian drone attack.

2026. g. 4. jūl. 23:01 UTC

The Nasdaq 100 Index is lower in after-hours trading, continuing a decline since Friday's close without any specific news to explain the movement.

2026. g. 4. jūl. 22:51 UTC

Brazil's Retail Sales MoM data set for July 8, 2026, shows cautious optimism as analysts predict recovery from April’s -1.5% decline amid positive economic sentiment linked to World Cup events.

2026. g. 4. jūl. 22:51 UTC

The DAX 30 Index is trading lower in after-market hours, reflecting a decline since Friday's close and contrasting with recent upward momentum.

2026. g. 4. jūl. 22:41 UTC

Cautious Optimism Grows Ahead of MBA Mortgage Rate Release Amid Easing Inflation and Weaker Jobs Data

2026. g. 4. jūl. 22:31 UTC

Japan's Current Account Data Release on July 7, 2026, Forecasts JPY 4.12 Trillion Surplus Amid Market Volatility and Global Economic Concerns.

2026. g. 4. jūl. 22:31 UTC

Brazil's Central Bank to Discuss SELIC Rate Amid Mixed Economic Signals and Global Influences on July 6, 2026.

2026. g. 4. jūl. 22:11 UTC

UK Housing Market Faces Continued Downward Pressure as RICS House Price Balance Forecasts -0.32% Amid Economic Challenges

2026. g. 4. jūl. 21:51 UTC

Japan's Household Spending YoY data set for July 6, 2026, expected to decline amid cautious market sentiment and global economic pressures.

2026. g. 4. jūl. 21:51 UTC

Japan's Household Spending Expected to Rise 1.4% in May Amid Mixed Economic Sentiment and Positive Service Sector Growth

2026. g. 4. jūl. 21:01 UTC

Macro News

Brent crude prices are lower in after-market hours following a Ukrainian drone attack on an oil terminal in St. Petersburg, intensifying the fuel crisis in Russia.

2026. g. 4. jūl. 20:21 UTC

ECB President Lagarde's upcoming speech sparks cautious market sentiment on Eurozone interest rate hikes amid easing inflation pressures.

Salīdzinājums

Cenas izmaiņa

Aclaris Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

91.91% augšup

Prognoze 12 mēnešiem

Vidējais 10.67 USD  91.91%

Augstākais 16 USD

Zemākais 4 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Aclaris Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

9 ratings

8

Pirkt

1

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
help-icon Live chat